Efficacy of Autologus serum therapy in patients with chronic autoimmune urticaria: A prospective, open label study conducted in a tertiary care centre, India
DOI:
https://doi.org/10.66344/jpad.v27i3.11Keywords:
Autologous serum therapy, Autologus serum skin test, Chronic autoimmune urticariaAbstract
Objective To evaluate the efficacy of repeated autologous serum injections in patients with chronic autoimmune urticaria.
Methods Patients of chronic autoimmune urticaria were prospectively analyzed for the efficacy of eight consecutive weekly autologous serum injections with a post-intervention follow-up of 12 weeks. Total urticaria severity score (TSS) was calculated at the baseline, at the end of treatment and lastly at the end of 12 weeks of follow-up. Response to therapy was judged by the percentage reduction in baseline TSS at the end of treatment and again at the end of 12 weeks of follow-up.
Results Out of the 65 patients enrolled, 4 opted out of study after one or the first few doses. Among the rest of the 61 patients, 16.4% patients showed excellent response and 55.7% showed good to fair response to autologous serum therapy. Poor response was seen in 27.9% of the study population. Among the responders, only 15.9% [out of 72] relapsed at the end of 12 weeks of follow-up and at the end of study protocol we had 60.7% of the study population who could be labeled as completely or partially remitted with the treatment regimen.
Conclusion Autologous serum therapy is an effective therapy in patients with chronic autoimmune urticaria. Better response is seen in female patients with short duration of disease.
References
1. O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197-201.
2. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599-604.
3. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 1996;106:1001-6.
4. Yadav S, Bajaj AK. Management of difficult urticaria. Indian J Dermatol. 2009;54:275-9.
5. Godse KV. Patch testing in chronic urticaria. Indian J Dermatol. 2009;54:188-9.
6. Alvarado Flores E, Avalos Diaz E, Diaz L, Herrera-Esparza R. Anti‑idiotype antibodies neutralize in vivo the blistering effect of pemphigus foliaceus IgG. Scand J Immunol. 2001;53:254‑8.
7. Majid I, Shah S, Hassan A, Aleem S, Aziz K. How effective is autologous serum therapy in chronic autoimmune urticaria. Indian J Dermatol. 2015;60:102.
8. Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol. 2008;74:109-13.
9. Debbarman P, Sil A, Datta PK, Bandyopadhyay D, Das NK. Autologous serum therapy in chronic urticaria: A promising complement to antihistamines. Indian J Dermatol. 2014;59:375-82.
10. Zuberbier T, Asero R, Bindslev Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM et al. EAACI/GA2LEN/EDF/WAO guideline: Management of urticaria. Allergy. 2009;64:1427-43.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Chintaginjala Aruna, Senthil Kumar A.L, Ramamurthy, Sridevi K, Swapna Kameti, Naga Swetha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
